|Bid||26.41 x 0|
|Ask||26.48 x 0|
|Day's range||26.11 - 26.65|
|52-week range||20.68 - 35.24|
|Beta (5Y monthly)||0.68|
|PE ratio (TTM)||38.84|
|Earnings date||22 Apr 2022 - 25 Apr 2022|
|Forward dividend & yield||0.14 (0.53%)|
|Ex-dividend date||23 May 2023|
|1y target est||38.34|
TOKYO and XIAMEN, China, March 27, 2023 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg and 80 mg. The AmoyDx® PLC Panel is based on polym
Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is CNY 18.12 per share, representing a market cap of CNY 10.419 billion.
Qiming Venture Partners announced today the closing of its latest funds totaling US$3.2 billion, including USD Fund VIII at US$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million).